Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This proof of concept study proposes targeted delivery of a broad-spectrum cytotoxic agent
(doxorubicin), via a specially formulated LTSL (ThermoDox®) activated by mild hyperthermia,
by using focused ultrasound (FUS), to achieve enhanced intra-tumoural doxorubicin
concentrations for the same systemic dose.
Adult patients with incurable confirmed hepatic primary or secondary tumours received a
single cycle of LTLD, followed by ultrasound-mediated hyperthermia to a single target liver
tumour. The primary endpoint relates to evidencing enhanced delivery of doxorubicin from LTLD
at the target tumour site, by comparing intratumoural concentrations of the drug before and
after focused ultrasound (FUS) exposure.